Charles Ross Carter Net Worth

The estimated Net Worth of Charles Ross Carter is at least $9.73 Mille dollars as of 8 December 2021. Mr Carter owns over 7,000 units of Icad Inc stock worth over $9,730 and over the last 3 years he sold ICAD stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Carter ICAD stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Icad Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 7,000 units of ICAD stock worth $49,350 on 8 December 2021.

The largest trade he's ever made was buying 7,000 units of Icad Inc stock on 8 December 2021 worth over $49,350. On average, Mr trades about 2,333 units every 0 days since 2021. As of 8 December 2021 he still owns at least 7,000 units of Icad Inc stock.

You can see the complete history of Mr Carter stock trades at the bottom of the page.

Mr. Charles Ross Carter biography

Charles Ross Carter is the CFO & Sec. at Icad Inc.

How old is Mr Carter?

Mr Carter is 54, he's been the CFO & Sec. of Icad Inc since . There are 6 older and 4 younger executives at Icad Inc. The oldest executive at Icad Inc is Michael S. Klein, 67, who is the Exec. Chairman & CEO.

What's Mr Carter's mailing address?

Charles's mailing address filed with the SEC is C/O ICAD INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA, NH, 03062.

Insiders trading at Icad Inc

Over the last 22 years, insiders at Icad Inc have traded over $10,970,060 worth of Icad Inc stock and bought 704,596 units worth $1,672,448 . The most active insiders traders include Anthony F Ecock, Nathaniel Dalton e Kevin C Burns. On average, Icad Inc executives and independent directors trade stock every 45 days with the average trade being worth of $39,056. The most recent stock trade was executed by Dana R Brown on 31 March 2023, trading 40,000 units of ICAD stock currently worth $52,000.

What does Icad Inc do?

icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.

Complete history of Mr Carter stock trades at Icad Inc

Icad Inc executives and stock owners

Icad Inc executives and other stock owners filed with the SEC include:

• Michael S. Klein,
  Exec. Chairman & CEO
• Stacey Stevens,
  President
• Jonathan Go,
  Chief Technology Officer
• Michael Klein,
  Executive Chairman of the Board, Chief Executive Officer
• Stacey M. Stevens,
  Pres
• Jonathan Go,
  Chief Technology Officer
• Andrew Sassine,
  Independent Director
• Susan Wood,
  Independent Director
• Rakesh Patel,
  Independent Director
• Jeremy Feffer,
  Investor Relations Contact Officer
• Nathaniel Dalton,
  Independent Director
• R. Scott Areglado,
  Chief Financial Officer
• Jeffrey Sirek,
  Chief Commercial Officer
• Brian Testa,
  Chief People Officer
• Annette L. Heroux,
  VP of Admin.
• Charles Ross Carter,
  CFO & Sec.
• Rachel Brem,
  Director
• Steven N Rappaport,
  Director
• Robert L Goodman,
  Director
• Dr Lawrence Howard,
  Director
• Anthony F Ecock,
  Director
• Timothy Norris Irish,
  Director
• Richard Christopher,
  Executive VP and CFO
• Andy Sassine,
  Director
• Somu Subramaniam,
  Director
• Elliot J Md Mba Sussman,
  Director
• Kenneth M Ferry,
  President, CEO
• James Harlan,
  Director
• George P Farley,
  Director
• W Scott Parr,
  Chief Executive Officer, Presi
• Herschell Sklaroff,
  Director
• John De Biase,
  Vice President of Sales
• Annette Heroux,
  Chief Financial Officer
• Steven K Rogers,
  Chief Scientific Officer
• Peter Farrell,
  EVP Marketing
• Thomas E Shoup,
  VP, Staff Operations
• James L Corbett,
  Chief Commercial Officer
• Kevin Woods,
  Vice President, Research & Dev
• Samuel Ronci,
  Vice President of Operations
• Robert Howard,
  Director
• Kevin C Burns,
  Executive VP of Finance, CFO
• Darlene M Deptula Hicks,
  Executive VP of Finance, CFO
• Maha Sallam,
  Executive Vice President
• Jeffrey H Barnes,
  Executive VP of Sales
• Dana R Brown,
  See Remarks
• Charles Ross Carter,
  CHIEF FINANCIAL OFFICER
• Hedvig Hricak,
  Director
• Daniel Joseph Shea,
  See Remarks
• Eric Lonnqvist,
  See Remarks
• Michael John Doyle,
  Director